Src family kinases differentially influence glioma growth and motility

Src-family kinase (SFK) signaling impacts multiple tumor-related properties, particularly in the context of the brain tumor glioblastoma. Consequently, the pan-SFK inhibitor dasatinib has emerged as a therapeutic strategy, despite physiologic limitations to its effectiveness in the brain. We investigated the importance of individual SFKs (Src, Fyn, Yes, and Lyn) to glioma tumor biology by knocking down individual SFK expression both in culture (LN229, SF767, GBM8) and orthotopic xenograft (GBM8) contexts.

Source: Molecular Oncology - June 9, 2015 Category: Cancer & Oncology Authors: Laura J. Lewis-Tuffin, Ryan Feathers, Priya Hari, Nisha Durand, Zhimin Li, Fausto J. Rodriguez, Katie Bakken, Brett Carlson, Mark Schroeder, Jann N. Sarkaria, Panos Z. Anastasiadis Source Type: research